PCVX

SEC source: 0001209191-21-011013 · doc4.xml · nonDerivative · entry 1

Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,399

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 9

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,405,418

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.27 to $29.11, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 8

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,412,050

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.27 to $28.26, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 7

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,419,617

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.27 to $27.26, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 6

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,446,305

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.27 to $26.26, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 5

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,483,576

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $29.11, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 4

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,577,316

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.49, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 3

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,666,072

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 to $27.49, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 2

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,704,320

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.02 to $26.18, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,733,242

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.02 to $26.01, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7), (8), (9), (10) and (11) to this Form 4.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000894 · form4.xml · nonDerivative · entry 2

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,784,116

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.24, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000894 · form4.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,786,884

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.56, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000781 · form4.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,801,118

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.22, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnotes (2) to this Form 4.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000662 · form4.xml · nonDerivative · entry 5

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,803,118

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.04 to $26.62, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000662 · form4.xml · nonDerivative · entry 4

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,805,258

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.60, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000662 · form4.xml · nonDerivative · entry 3

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,806,631

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.99, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001209191-21-005892 · doc4.xml · derivative · entry 6

Fairman Jeff · CIK 0001813800 · VP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,759

Underlying: Common Stock · 4,750 shares

Expires 2025-04-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.

SEC source: 0001209191-21-005892 · doc4.xml · nonDerivative · entry 3

Fairman Jeff · CIK 0001813800 · VP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,408

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.885 to $26.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-005892 · doc4.xml · nonDerivative · entry 2

Fairman Jeff · CIK 0001813800 · VP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,833

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.82 to $25.745. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-005892 · doc4.xml · nonDerivative · entry 1

Fairman Jeff · CIK 0001813800 · VP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,158

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-21-000662 · form4.xml · nonDerivative · entry 2

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,823,400

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.27, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000662 · form4.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,838,861

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $26.00, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000557 · form4.xml · nonDerivative · entry 3

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,858,372

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.58, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000557 · form4.xml · nonDerivative · entry 2

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,869,755

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001209191-21-004750 · doc4.xml · derivative · entry 3

Wassil Jim · CIK 0001813798 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 248,926

Underlying: Common Stock · 3,000 shares

Expires 2029-12-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.

SEC source: 0001209191-21-004750 · doc4.xml · nonDerivative · entry 2

Wassil Jim · CIK 0001813798 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,381

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.50 to $25.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-004750 · doc4.xml · nonDerivative · entry 1

Wassil Jim · CIK 0001813798 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,381

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,562 shares acquired under the Employment Stock Purchase Plan on November 17, 2020.

SEC source: 0001062993-21-000557 · form4.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,869,855

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.77, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000448 · form4.xml · nonDerivative · entry 5

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,888,901

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.35, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000448 · form4.xml · nonDerivative · entry 4

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,895,901

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.99, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001209191-21-004743 · doc4.xml · derivative · entry 5

PICKERING GRANT · CIK 0001258693 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 478,815

Underlying: Common Stock · 15,000 shares

Expires 2027-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter.

SEC source: 0001209191-21-004743 · doc4.xml · nonDerivative · entry 3

PICKERING GRANT · CIK 0001258693 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 578,691

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.71 to $26.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-004743 · doc4.xml · nonDerivative · entry 2

PICKERING GRANT · CIK 0001258693 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 580,258

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.66 to $25.655. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-004743 · doc4.xml · nonDerivative · entry 1

PICKERING GRANT · CIK 0001258693 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 593,691

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-21-000448 · form4.xml · nonDerivative · entry 3

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,938,417

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $26.15, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000448 · form4.xml · nonDerivative · entry 2

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,942,225

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.03 to $26.02, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001209191-21-004102 · doc4.xml · derivative · entry 3

Wright-Mitchell Jane · CIK 0001614568 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,968

Underlying: Common Stock · 2,500 shares

Expires 2029-03-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on January 7, 2020, and 1/48 of the shares vest monthly thereafter.

SEC source: 0001209191-21-004102 · doc4.xml · nonDerivative · entry 2

Wright-Mitchell Jane · CIK 0001614568 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,562

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001209191-21-004102 · doc4.xml · nonDerivative · entry 1

Wright-Mitchell Jane · CIK 0001614568 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,062

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,562 shares acquired under the Employee Stock Purchase Plan on November 17, 2020.

SEC source: 0001062993-21-000448 · form4.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,965,094

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.41 to $26.35, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6) and (7) to this Form 4.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000354 · form4.xml · nonDerivative · entry 7

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,980,012

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.42, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000354 · form4.xml · nonDerivative · entry 6

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,983,112

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $26.25, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000354 · form4.xml · nonDerivative · entry 5

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 2,009,122

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.90 to $27.36, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000354 · form4.xml · nonDerivative · entry 4

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 2,010,023

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.90 to $26.89, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001209191-21-003345 · doc4.xml · derivative · entry 4

Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,426

Underlying: Common Stock · 2,500 shares

Expires 2027-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter.

SEC source: 0001209191-21-003345 · doc4.xml · nonDerivative · entry 3

Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,899

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $26.35 to $27.06. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-003345 · doc4.xml · nonDerivative · entry 2

Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,426

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.08 to $25.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-003345 · doc4.xml · nonDerivative · entry 1

Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,399

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,284 shares acquired under the Employee Stock Purchase Plan on November 17, 2020.

SEC source: 0001062993-21-000354 · form4.xml · nonDerivative · entry 3

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 2,027,689

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.08, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-000354 · form4.xml · nonDerivative · entry 2

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 2,039,895

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.99, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.